Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;35(1):245-249.
doi: 10.1038/s41375-020-0800-6. Epub 2020 Mar 19.

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

Isabel Cuenca #  1 , Daniel Alameda #  2 , Beatriz Sanchez-Vega  1 , David Gomez-Sanchez  3 , Diego Alignani  2 , Marta Lasa  2 , Esther Onecha  1 , Ramon Lecumberri  2 , Felipe Prosper  2 , Enrique M Ocio  4 , Maria Esther González  5 , Alfonso García de Coca  6 , Javier De La Rubia  7 , Mercedes Gironella  8 , Luis Palomera  9 , Albert Oriol  10 , Maria Casanova  11 , Valentin Cabañas  12 , Francisco Taboada  13 , Albert Pérez-Montaña  14 , Felipe De Arriba  15 , Noemi Puig  16 , Gonzalo Carreño-Tarragona  1 , Santiago Barrio  1 , Jose Enrique de la Puerta  17 , Angel Ramirez-Payer  13 , Isabel Krsnik  18 , Juan Jose Bargay  19 , Juan Jose Lahuerta  1 , Maria-Victoria Mateos  16 , Jesus F San-Miguel  2 , Bruno Paiva  2 , Joaquin Martinez-Lopez  20
Affiliations

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

Isabel Cuenca et al. Leukemia. 2021 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1. Genes recurrently mutated in AL.
Distribution per patient of the most frequently mutated genes (n = 37). Boxes were colored according to the type of mutation. Top barplots define the total number of mutations per patient.
Fig. 2
Fig. 2. The mutational landscape in AL and MM.
a Number of mutations in patients with newly diagnosed AL and MM. b Shared and private mutations between AL and MM. c Driver genes based in its recurrence in AL and MM. d Predominant Ig heavy chain gene rearrangements used in AL and MM.
See this image and copyright information in PMC

References

    1. Merker JD, Valouev A, Gotlib J. Next-generation sequencing in hematologic malignancies: what will be the dividends? Ther Adv Hematol. 2012;3:333–9. doi: 10.1177/2040620712458948. - DOI - PMC - PubMed
    1. Paiva B, Martinez-Lopez J, Corchete LA, Sanchez-Vega B, Rapado I, Puig N, et al. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis. Blood. 2016;127:3035–9. doi: 10.1182/blood-2015-10-673095. - DOI - PubMed
    1. Boyle EM, Ashby C, Wardell CP, Rowczenio D, Sachchithanantham S, Wang Y, et al. The genomic landscape of plasma cells in systemic light chain amyloidosis. Blood. 2018;132:2775–7. doi: 10.1182/blood-2018-08-872226. - DOI - PubMed
    1. Merlini G, Comenzo RL, Seldin DC, Wechalekar A, Gertz MA. Immunoglobulin light chain amyloidosis. Expert Rev Hematol. 2014;7:143–56. doi: 10.1586/17474086.2014.858594. - DOI - PubMed
    1. Puig N, Paiva B, Lasa M, Burgos L, Perez JJ, Merino J, et al. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis. Leukemia. 2019;33:1256–67. doi: 10.1038/s41375-018-0308-5. - DOI - PubMed

Publication types

MeSH terms